Table 2. Availability of anti-diabetic medicines in public hospitals and private pharmacies in Shaanxi Province, China in 2015 (%).

	Tertiary hospital		Secondary hospital		Primary hospital		Hospitals with mark-up		Hospitals without mark-up		All public hospitals		All private pharmacies
	OBs	Gs	OBs	Gs	OBs	Gs	OBs	Gs	OBs	Gs	OBs	Gs	OBs	Gs
Acarbose	100.0	58.3	83.3	29.2	47.2	19.4	9.1	36.4	4.9	23.1	68.1	29.2	91.7	50.0
Glibenclamide	/	8.3	/	0	0	5.6	/	9.1	/	2.6	/	5.6	/	20.8
Gliclazide	83.3	25.0	58.3	45.8	25.0	22.2	66.7	36.4	23.1	25.6	45.8	30.6	83.3	75.0
Glimepiride	50.0	58.3	25.0	29.2	5.6	22.2	36.4	42.4	5.1	2.1	19.4	19.4	29.2	80.6
Glipizide	16.7	50.0	4.2	50.0	2.8	44.4	9.1	48.5	2.6	46.2	5.6	47.2	5.6	80.6
Metformin	44.4	91.7	58.3	100.0	25.0	91.7	69.7	97.0	20.5	92.3	44.4	94.4	81.9	97.2
Pioglitazone	16.7	33.3	0	0	0	0	6.1	21.2	0	0	2.8	29.2	0	31.9
Repaglinide	100.0	25.0	66.7	4.2	30.6	0	81.8	12.1	30.8	0	54.2	54.2	16.7	79.2
Mean	58.7	43.7	42.3	32.3	19.5	25.7	39.8	37.9	12.4	24.0	34.3	28.7	44.1	64.4

/: No data for this medicine, because the original brand of glibenclamide were not used in Shaanxi Province. OBs: originator brands. Gs: generics.